Compare BIO & KNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BIO | KNX |
|---|---|---|
| Founded | 1952 | 1989 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Laboratory Analytical Instruments | Trucking Freight/Courier Services |
| Sector | Industrials | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.2B | 7.0B |
| IPO Year | N/A | 1994 |
| Metric | BIO | KNX |
|---|---|---|
| Price | $301.03 | $53.61 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 17 |
| Target Price | ★ $358.50 | $54.59 |
| AVG Volume (30 Days) | 173.1K | ★ 3.3M |
| Earning Date | 02-12-2026 | 01-21-2026 |
| Dividend Yield | N/A | ★ 1.35% |
| EPS Growth | N/A | ★ 280.63 |
| EPS | N/A | ★ 0.88 |
| Revenue | $2,557,500,000.00 | ★ $7,477,640,000.00 |
| Revenue This Year | $1.77 | $2.37 |
| Revenue Next Year | $2.30 | $5.55 |
| P/E Ratio | ★ N/A | $60.90 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $211.43 | $36.69 |
| 52 Week High | $373.69 | $61.51 |
| Indicator | BIO | KNX |
|---|---|---|
| Relative Strength Index (RSI) | 41.67 | 70.72 |
| Support Level | $295.01 | $51.68 |
| Resistance Level | $307.07 | $53.79 |
| Average True Range (ATR) | 8.47 | 1.38 |
| MACD | -1.47 | 0.07 |
| Stochastic Oscillator | 20.90 | 89.29 |
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (60% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (about 40% of sales), Europe (about 30%), Asia (about 30%), and other. Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.
Knight-Swift is the largest full-truckload carrier in the US, with a diversified transportation offering. Pro forma for the US Xpress deal, about 82% of revenue derives from Knight's asset-based trucking business, with full truckload (for-hire dry van, refrigerated, and dedicated contract) making up 69% and less than truckload 13%. Truck brokerage and other asset-light logistics services make up 9% of revenue, with intermodal near 6%. Knight's intermodal operations use the Class I railroads for the underlying movement of its shipping containers and include drayage (regional trucking services to and from inland intermodal ramps/terminals). The remainder of revenue reflects services offered to shippers and third-party truckers, including equipment maintenance and leasing.